ABSTRACT
von Willebrand disease (VWD) is the most common inherited bleeding disorder and arises from deficiencies and/or defects in the plasma protein von Willebrand factor (VWF). The current report overviews the diagnosis and management of VWD as reflected by differential processes applied within centers around the world. The prevalence of VWD, as well as the frequency of different VWD types, is also reported. VWD prevalence data varies according to methodology used, with epidemiological/population screening estimates approximating 1% of the population (or 10,000 cases per million population), several orders of magnitude higher than estimates from bleeding disorders registry data or regional/center analysis (which instead range from <1 to ~450 cases per million population). Frequency of different VWD types also varies according to source and analysis, with type 1 VWD identified as the clear dominant type in most developed countries (ranging from 40% to 90% of all VWD cases), whereas type 3 VWD predominates in developing countries such as India and Iran. The frequency of qualitative (i.e., type 2) VWD also varies considerably among different reports, ranging from 3% to >50% of all VWD cases, as does the frequency of specific qualitative VWD types (i.e., 2A, 2B, 2M, and 2N). Although type 2A VWD is considered the most common form of type 2 VWD, in some reports workers consider type 2M VWD to be as, or more, common. Although not considered to be a “true” VWD, given its platelet origin, platelet-type VWD is only rarely identified. Finally, management of VWD also differs according to geographic region. Most developed countries use standard therapy, employing desmopressin (DDAVP) wherever possible, factor concentrate in other situations, and antifibrinolytic therapy as required. In contrast, the relative high cost and unavailability of factor concentrates in developing countries, and sometimes the unavailability of DDAVP, requires different management strategies to be applied.
KEYWORDS
von Willebrand disease - VWD - diagnosis - management - desmopressin - DDAVP - genetic testing - factor concentrates
REFERENCES
-
1
Casonato A, Daidone V, Padrini R.
Assessment of von Willebrand factor propeptide improves the diagnosis of von Willebrand disease.
Semin Thromb Hemost.
2011;
37
(5)
456-463
-
2
Othman M.
Platelet-type von Willebrand disease: a rare, often misdiagnosed and underdiagnosed bleeding disorder.
Semin Thromb Hemost.
2011;
37
(5)
464-469
-
3
Hamilton A, Ozelo M, Leggo J et al..
Frequency of platelet type versus type 2B von Willebrand disease: an international registry-based study.
Thromb Haemost.
2011;
105
(3)
501-508
-
4
Hampshire D J, Goodeve A C.
The International Society on Thrombosis and Haematosis von Willebrand disease database: an update.
Semin Thromb Hemost.
2011;
37
(5)
470-479
-
5
de Wee E M, Leebeek F WG, Eikenboom JCJ.
Diagnosis and management of von Willebrand disease in the Netherlands.
Semin Thromb Hemost.
2011;
37
(5)
480-487
-
6
Keeney S, Collins P, Cumming A, Goodeve A, Pasi J.
Diagnosis and management of von Willebrand disease in the United Kingdom.
Semin Thromb Hemost.
2011;
37
(5)
488-494
-
7
Lassila R, Holme P A, Landorph A, Petrini P, Önundarson P T, Hillarp A.
Nordic Haemophilia Council's practical guidelines on diagnosis and management of von Willebrand disease.
Semin Thromb Hemost.
2011;
37
(5)
495-502
-
8
Batlle J, Perez-Rodriguez A, Prego JCP, Fraga E L, Rodriguez-Trillo A, Lopez-Fernandez M F. on behalf of participant investigators and centres .
Diagnosis and management of von Willebrand disease in Spain.
Semin Thromb Hemost.
2011;
37
(5)
503-510
-
9
Federici A B, Bucciarelli P, Castaman G, Baronciani L, Canciani M T, Mazzucconi M G, Morfini M, Rocino A, Schiavoni M, Oliovecchio E, Iorio A, Mannucci P M.
Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1,234 patients.
Semin Thromb Hemost.
2011;
37
(5)
511-521
-
10
James P D, Lillicrap D P.
The diagnosis and management of von Willebrand disease in Canada.
Semin Thromb Hemost.
2011;
37
(5)
522-527
-
11
Flood V H, Gill J C, Bellissimo D B, Haberichter S L, Friedman K D, Montgomery R R.
von Willebrand disease in the United States: a perspective from Wisconsin.
Semin Thromb Hemost.
2011;
37
(5)
528-534
-
12
Rodgers S E, Lloyd J V, Mangos H M, Duncan E M, McRae S J.
Diagnosis and management of adult patients with von Willebrand disorder in South Australia.
Semin Thromb Hemost.
2011;
37
(5)
535-541
-
13
Favaloro E J, Bonar R, Favaloro J, Koutts J.
Diagnosis and management of von Willebrand disease in Australia.
Semin Thromb Hemost.
2011;
37
(5)
542-554
-
14
Rajagopal R, Smith M P.
Diagnosis of von Willebrand disease in South Island, New Zealand.
Semin Thromb Hemost.
2011;
37
(5)
555-559
-
15
Bonduel M, Frontroth J P, Hepner M, Sciuccati G, Feliu-Torres A, Pieroni G.
von Willebrand disease in children: diagnosis and management of a pediatric cohort in one single center in Argentina.
Semin Thromb Hemost.
2011;
37
(5)
560-567
-
16
Woods A I, Luceros A S, Meschengieser S S, Kempfer A C, Blanco A N, Lazzari M A.
Diagnosis and management of von Willebrand disease in a single institution of Argentina.
Semin Thromb Hemost.
2011;
37
(5)
568-575
-
17
Meiring M, Coetzee M, Kelderman M, Badenhorst P.
Laboratory diagnosis and management of von Willebrand disease in South Africa.
Semin Thromb Hemost.
2011;
37
(5)
576-580
-
18
Akin M, Kavakli K.
Laboratory diagnosis and management of von Willebrand disease in Turkey: Izmir experience.
Semin Thromb Hemost.
2011;
37
(5)
581-586
-
19
Nair S C, Viswabandya A, Srivastava A.
Diagnosis and management of von Willebrand disease (VWD): a developing country perspective.
Semin Thromb Hemost.
2011;
37
(5)
581-586
-
20
Ghosh K, Shetty S.
Epidemiology, diagnosis and management of von Willebrand disease in India.
Semin Thromb Hemost.
2011;
37
(5)
595-601
-
21
Cohan N, Karimi M.
Diagnosis and management of von Willebrand disease in Iran.
Semin Thromb Hemost.
2011;
37
(5)
602-606
-
22
Xu J, Yu Z, Zhang L, Ruan C, Yang R.
Diagnosis and management of von Willebrand disease in China.
Semin Thromb Hemost.
2011;
37
(5)
607-614
-
23
Sadler J E, Budde U, Eikenboom J C Working Party on von Willebrand Disease Classification et al.
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.
J Thromb Haemost.
2006;
4
(10)
2103-2114
-
24
Favaloro E J.
Identification and functional characterisation of von Willebrand disease.
US Hematology.
2009;
2
(1)
16-23
-
25
Favaloro E J.
Toward a new paradigm for the identification and functional characterization of von Willebrand disease.
Semin Thromb Hemost.
2009;
35
(1)
60-75
-
26
Favaloro E J.
An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult.
Semin Thromb Hemost.
2007;
33
(8)
727-744
-
27
Favaloro E J, Krigstein M, Koutts J, Brighton T, Lindeman R.
Genetic testing for the diagnosis of von Willebrand disease: benefits and limitations.
J Coag Disorders.
2010;
2
37-47
-
28
Favaloro E J.
Genetic testing for von Willebrand disease: the case against.
J Thromb Haemost.
2010;
8
(1)
6-12
-
29
Rodeghiero F, Tosetto A, Abshire T ISTH/SSC joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group et al.
ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders.
J Thromb Haemost.
2010;
8
(9)
2063-2065
-
30
Favaloro E J, Lippi G, Franchini M.
Contemporary platelet function testing.
Clin Chem Lab Med.
2010;
48
(5)
579-598
-
31
Othman M, Favaloro E J.
Genetics of type 2B von Willebrand disease: “true 2B,” “tricky 2B,” or “not 2B.” What are the modifiers of the phenotype?.
Semin Thromb Hemost.
2008;
34
(6)
520-531
-
32
Federici A B, Mannucci P M, Castaman G et al..
Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients.
Blood.
2009;
113
(3)
526-534
-
33
Frontroth J P, Hepner M, Sciuccati G, Feliú Torres A, Pieroni G, Bonduel M.
Prospective study of low-dose ristocetin-induced platelet aggregation to identify type 2B von Willebrand disease (VWD) and platelet-type VWD in children.
Thromb Haemost.
2010;
104
(6)
1158-1165
-
34
Ribba A S, Loisel I, Lavergne J M et al..
Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen.
Thromb Haemost.
2001;
86
(3)
848-854
-
35
Riddell A F, Gomez K, Millar C M et al..
Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor.
Blood.
2009;
114
(16)
3489-3496
-
36
Flood V H, Lederman C A, Wren J S et al..
Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD.
J Thromb Haemost.
2010;
8
(6)
1431-1433
-
37
Melo-Nava B M, Benítez H, Palacios J J et al..
Molecular study of VWF gene from Mexican mestizo patients with von Willebrand disease, and the finding of three new mutations.
Blood Cells Mol Dis.
2007;
39
(3)
361-365
-
38
Favaloro E J, Mohammed S, Koutts J.
Identification and prevalence of von Willebrand disease type 2N (Normandy) in Australia.
Blood Coagul Fibrinolysis.
2009;
20
(8)
706-714
-
39
Favaloro E J.
Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin?.
Semin Thromb Hemost.
2008;
34
(1)
113-127
-
40
Sadler J E.
Low von Willebrand factor: sometimes a risk factor and sometimes a disease.
Hematology (Am Soc Hematol Educ Program).
2009;
106-112
-
41
Favaloro E J, Thom J, Baker R. Australasian Society for Thrombosis and Haemostasis (ASTH) Emerging Technologies Group .
Assessment of current diagnostic practice and efficacy in testing for von Willebrand's disorder: results from the second Australasian multi-laboratory survey.
Blood Coagul Fibrinolysis.
2000;
11
(8)
729-737
-
42
Favaloro E J, Bonar R, Marsden K. on behalf of the RCPA QAP Haemostasis Committee .
Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification.
Clin Lab Sci.
2008;
21
(3)
178-183
-
43
Favaloro E J, Lippi G, Adcock D M.
Preanalytical and postanalytical variables: the leading causes of diagnostic error in hemostasis?.
Semin Thromb Hemost.
2008;
34
(7)
612-634
-
44
Favaloro E J, Bonar R, Meiring M, Street A, Marsden K. RCPA QAP in Haematology .
2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2B VWD.
Thromb Haemost.
2007;
98
(2)
346-358
-
45
Favaloro E J, Bonar R, Kershaw G on behalf of the RCPA QAP in Haematology et al.
Reducing errors in identification of von Willebrand disease: the experience of the Royal College of Pathologists of Australasia quality assurance program.
Semin Thromb Hemost.
2006;
32
(5)
505-513
-
46
Favaloro E J.
Laboratory identification of von Willebrand disease: technical and scientific perspectives.
Semin Thromb Hemost.
2006;
32
(5)
456-471
-
47
Favaloro E J.
Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease.
Thromb Haemost.
2010;
104
(5)
1009-1021
-
48
Meijer P, Haverkate F.
An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation.
Semin Thromb Hemost.
2006;
32
(5)
485-491
-
49
Favaloro E J.
Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD): a rebuttal.
J Thromb Haemost.
2008;
6
(11)
1999-2001
author reply 2002-2003
-
50
Rodeghiero F, Castaman G, Tosetto A.
Optimizing treatment of von Willebrand disease by using phenotypic and molecular data.
Hematology (Am Soc Hematol Educ Program).
2009;
113-123
-
51
Favaloro E J, Thom J, Patterson D et al..
Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?.
Thromb Res.
2009;
123
(6)
862-868
-
52
Favaloro E J, Thom J, Patterson D et al..
Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease.
Blood Coagul Fibrinolysis.
2009;
20
(6)
475-483
-
53
Favaloro E J.
Rethinking the diagnosis of von Willebrand disease.
Thromb Res.
2011;
127
(Suppl 2)
S17-S21
-
54
Keeney S, Bowen D, Cumming A, Enayat S, Goodeve A, Hill M. UK Haemophilia Centre Doctors' Organisation (UKHCDO) .
The molecular analysis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organisation Haemophilia Genetics Laboratory Network.
Haemophilia.
2008;
14
(5)
1099-1111
-
55
Stonebraker J S, Bolton-Maggs P H, Soucie J M, Walker I, Brooker M.
A study of variations in the reported haemophilia A prevalence around the world.
Haemophilia.
2010;
16
(1)
20-32
-
56
Rodeghiero F, Castaman G, Dini E.
Epidemiological investigation of the prevalence of von Willebrand's disease.
Blood.
1987;
69
(2)
454-459
-
57
Castaman G, Eikenboom J C, Bertina R M, Rodeghiero F.
Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation.
Thromb Haemost.
1999;
82
(3)
1065-1070
-
58
Biron C, Mahieu B, Rochette A et al..
Preoperative screening for von Willebrand disease type 1: low yield and limited ability to predict bleeding.
J Lab Clin Med.
1999;
134
(6)
605-609
-
59
Werner E J, Broxson E H, Tucker E L, Giroux D S, Shults J, Abshire T C.
Prevalence of von Willebrand disease in children: a multiethnic study.
J Pediatr.
1993;
123
(6)
893-898
-
60 Gürsel T, Kavaklı K, Aktuğlu G et al.. Hemofili ve von Willebrand Hastalığında Tanı ve Tedavi, Türk Hematoloji Derneği-Hemofili Alt Komitesi (Turkish Guideline). İstanbul, Turkey: Rehberi; 1999: 2-5
-
61
Yilmaz D, Karapınar B, Yeniay B S, Balkan C, Bilenoğlu B, Kavaklı K.
İzmir'de von Willebrand Hastalığı sıklığını belirtmeye yönelik epidemiyolojik çalışma [in Turkish].
Ege Pediatri Bülteni.
2005;
12
(3)
151-159
-
62
Cabrera M E, Artigas C G, Páez E et al..
von Willebrand's disease in the IX Region of Chile.
Rev Med Chil.
1989;
117
(4)
423-430
-
63
Diez-Ewald M, Vizcaíno G, Arteaga-Vizcaíno M, Fernández N, Weir-Medina J, Gómez O.
Epidemiology of von Willebrand's disease in the state of Zulia, Venezuela.
Invest Clin.
1991;
32
(4)
187-199
-
64
Zhang L, Li H, Zhao H, Zhang X, Ji L, Yang R.
Retrospective analysis of 1312 patients with haemophilia and related disorders in a single Chinese institute.
Haemophilia.
2003;
9
(6)
696-702
-
65
Sadler J E, Mannucci P M, Berntorp E et al..
Impact, diagnosis and treatment of von Willebrand disease.
Thromb Haemost.
2000;
84
(2)
160-174
-
66
Iorio A, Oliovecchio E, Morfini M, Mannucci P M. Association of Italian Hemophilia Centres Directors .
Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis.
Haemophilia.
2008;
14
(3)
444-453
-
67 Canadian Hemophilia Registry .Available at: http://fhs.mcmaster.ca/chr/data.html Accessed December 27, 2010
-
68 World Federation for Haemophilia. 2008 Report. Available at: http://www.wfh.org/2/docs/Publications/.../2008_Global_Survey_Report.pdf Accessed February 18, 2011
-
69
Woods A I, Meschengieser S S, Blanco A N et al..
Clinical features and laboratory patterns in a cohort of consecutive Argentinian patients with von Willebrand's disease.
Haematologica.
2001;
86
(4)
420-427
-
70
Zhang J Y, Wang Y C, Yang L et al..
Retrospective analysis of 100 patients with von Willebrand disease.
Clin Focus.
2003;
18
581-582
-
71
Kumar S, Kishore R, Gupta V, Jain M, Shukla J.
Prevalence and spectrum of von Willebrand disease in eastern Uttar Pradesh.
Indian J Pathol Microbiol.
2010;
53
(3)
486-489
-
72
Trasi S, Shetty S, Ghosh K, Mohanty D.
Prevalence and spectrum of von Willebrand disease from western India.
Indian J Med Res.
2005;
121
(5)
653-658
-
73
Rezende S M, Pinheiro K, Caram C, Genovez G, Barca D.
Registry of inherited coagulopathies in Brazil: first report.
Haemophilia.
2009;
15
(1)
142-149
-
74
Tagliaferri A, Rivolta G F, Biasoli C et al..
A web-based registry of inherited bleeding disorders in the region of Emilia-Romagna: results at three and a half years.
Haemophilia.
2008;
14
(2)
343-354
-
75
Michiels J J, van de Velde A, van Vliet H H, van der Planken M, Schroyens W, Berneman Z.
Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
Semin Thromb Hemost.
2002;
28
(2)
111-132
-
76
Michiels J J, van Vliet H H, Berneman Z et al..
Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Clin Appl Thromb Hemost.
2007;
13
(1)
14-34
-
77
Federici A B, Mazurier C, Berntorp E et al..
Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study.
Blood.
2004;
103
(6)
2032-2038
-
78
Lee C A, Hubbard A, Sabin C A on behalf of the ISTH-SSC sub-committee on VWF et al.
Laboratory diagnosis of von Willebrand disease: results from a prospective and blind study in 32 laboratories worldwide using lyophilized plasmas.
J Thromb Haemost.
2010;
9
220-222
Emmanuel J FavaloroPh.D. F.F.Sc. (RCPA)
Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR)
Westmead Hospital, Westmead, NSW, 2145, Australia
eMail: emmanuel.favaloro@swahs.health.nsw.gov.au
